Everest Medicines First Half 2025 Earnings: CN¥0.77 loss per share (vs CN¥1.97 loss in 1H 2024)

Everest Medicines (HKG:1952) First Half 2025 Results

Key Financial Results

• Revenue: CN¥446.1m (up 48% from 1H 2024).
• Net loss: CN¥249.8m (loss narrowed by 61% from 1H 2024).
• CN¥0.77 loss per share (improved from CN¥1.97 loss in 1H 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Everest Medicines Earnings Insights

Looking ahead, revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are down 14% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Everest Medicines' balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.